AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

โ† Trials
๐Ÿงช

Dose-Finding Study of HUC1-394 in Participants With Dry Eye Disease

RecruitingPhase 2Ages 19 Years - anyAllHuons Co., Ltd.
๐Ÿ’ฌ

In plain words

What the trial is, and whether it could suit you

Clinical trial aims to determine the optimal dosing regimen by evaluating the efficacy and safety of HUC1-394 across different dosing frequencies in patients with moderate to severe dry eye disease.

Sign in to get the eligibility rules as simple questions to take to your doctor.

๐Ÿ“‹ Eligibility rules (as published)
Inclusion Criteria: * Adults aged โ‰ฅ 19 years at the time of screening * Trial participants who have experienced at least one of the following dry eye disease symptoms for at least 3 months prior to the time of screening * Trial participants who meet all of the following criteria in at least one eye (left or right) at the time of screening and randomization: TCSS (NEI grading) โ‰ฅ 4 / Non-anesthetic Schirmer test result \> 0 mm and โ‰ค 10 mm/5 min / TBUT \< 7 seconds * OSDI score โ‰ฅ 23 at the time of screening * Trial participants who have provided voluntary written informed consent after receiving a full explanation and understanding of the clinical trial Exclusion Criteria: * Trial participants with clinically significant ophthalmic diseases that may confound the interpretation of clinical trial results * Trial participants with blepharospasm, entropion, ectropion, or abnormalities of the eyelashes * Trial participants with any active ophthalmic disease that may affect the ocular surface, such as active allergy, anterior uveitis, and Stevens-Johnson syndrome * Trial participants with a history of corneal transplantation or neurotrophic keratitis * Trial participants with autoimmune diseases or immunodeficiency disorders * Pregnant or lactating women, or women of childbearing potential and men of reproductive potential who plan to conceive during the clinical trial or are unwilling to use an appropriate method of contraception * Trial participants who have participated in another clinical trial and received an investigational product or used an investigational medical device within 30 days prior to the time of screening * Trial participants who are deemed ineligible for participation by the investigator for any other reason in the clinical trial
๐Ÿ’Š

What it tests

  • HUC1-394
  • Placebo
๐Ÿ“

Where

1 site
Yonsei University Health System, Severance Hospital
Seoul, South Korea
๐Ÿค Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible โ€” always decide together with your own doctor.
๐Ÿ›ก๏ธ

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it โ€” not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use ยท Privacy